This company listing is no longer active
Calliditas Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Calliditas Therapeutics's earnings have been declining at an average annual rate of -22.5%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 59.4% per year.
Belangrijke informatie
-22.5%
Groei van de winst
-18.5%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 6.0% |
| Inkomstengroei | 59.4% |
| Rendement op eigen vermogen | -449.8% |
| Nettomarge | -30.0% |
| Volgende winstupdate | 11 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Opbrengsten en kosten
Hoe Calliditas Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,601 | -480 | 1,314 | 558 |
| 31 Mar 24 | 1,311 | -525 | 1,163 | 526 |
| 31 Dec 23 | 1,207 | -466 | 1,061 | 502 |
| 30 Sep 23 | 1,184 | -451 | 1,040 | 498 |
| 30 Jun 23 | 1,150 | -292 | 968 | 421 |
| 31 Mar 23 | 944 | -393 | 872 | 428 |
| 31 Dec 22 | 803 | -412 | 775 | 415 |
| 30 Sep 22 | 405 | -628 | 653 | 413 |
| 30 Jun 22 | 343 | -608 | 562 | 402 |
| 31 Mar 22 | 279 | -576 | 474 | 381 |
| 31 Dec 21 | 229 | -500 | 390 | 357 |
| 30 Sep 21 | 199 | -452 | 302 | 331 |
| 30 Jun 21 | 0 | -600 | 248 | 304 |
| 31 Mar 21 | 0 | -501 | 182 | 277 |
| 31 Dec 20 | 1 | -433 | 142 | 241 |
| 30 Sep 20 | 47 | -286 | 102 | 209 |
| 30 Jun 20 | 47 | -198 | 71 | 190 |
| 31 Mar 20 | 185 | -54 | 71 | 173 |
| 31 Dec 19 | 185 | -33 | 63 | 150 |
| 30 Sep 19 | 138 | -54 | 47 | 142 |
| 30 Jun 19 | 138 | -35 | 44 | 120 |
| 31 Mar 19 | 0 | -136 | 33 | 99 |
| 31 Dec 18 | 0 | -132 | 31 | 99 |
| 30 Sep 18 | 0 | -128 | 64 | 65 |
| 30 Jun 18 | 0 | -115 | 74 | 41 |
| 31 Mar 18 | 0 | -113 | 81 | 31 |
| 31 Dec 17 | 0 | -87 | 85 | 0 |
| 31 Dec 16 | 0 | -57 | 56 | 0 |
Kwaliteitswinsten: CALT is currently unprofitable.
Groeiende winstmarge: CALT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CALT is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Versnelling van de groei: Unable to compare CALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CALT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Rendement op eigen vermogen
Hoge ROE: CALT has a negative Return on Equity (-449.83%), as it is currently unprofitable.